CX3CL1 and neoplasm: The CX3CL1 variant was validated by target sequencing in both tumors at heterogeneity (Figure 2B); however, Sanger sequencing detected the mutation only in the tumor sample with the higher variant frequency (HB33, 40%) but did not detect in additional 47 HB samples.